InveniAI and Kyowa Kirin Announce Achievement of Milestone in Research Collaboration

– Collaboration poised to exploit synergistic drug discovery and development engine to enable innovation at scale by InveniAI and validation of prioritized concepts in preclinical studies by Kyowa Kirin

InveniAI LLC, a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug and target discovery and development, and Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology,  announced the achievement of the first milestone in disease model systems that triggered a milestone payment that has been received by InveniAI under the research collaboration between the companies.

Latest Aithority Insights: Top Skills Needed to Become an AI Engineer

Yoshifumi Torii, Ph.D., Executive Officer, Vice President, and Head of R&D Division of Kyowa Kirin, added, “We are excited to achieve a successful outcome by leveraging InveniAI’s platform AlphaMeld that detected very early signals of association between targets/mechanism of action and clinical utility based on the platform’s analytics. We have since validated this program which, as predicted, has shown signals of efficacy in preclinical proof-of-concept studies for the treatment of a disease indication where current therapeutic options lack efficacy and have adverse effects. We are eager to test this very promising candidate for further studies. We also look forward to the selection of additional novel programs identified by InveniAI’s truly game-changing platform and believe that our collaboration will contribute to addressing enduring unmet medical needs.”

Top Machine Learning Insights: LivePerson Collaborates with UCSC to Build the Future of Natural…

“We are delighted with the progress of our synergistic collaboration with Kyowa Kirin and the advancement of an AI-identified target and associated clinical utility at unprecedented speed,” said InveniAI’s President and Chief Executive Officer, Krishnan Nandabalan, Ph.D., “Our AI-powered drug and target discovery platform, AlphaMeld, has repeatedly demonstrated the ability to generate concepts that have been validated by our partners from preclinical to late-stage clinical success. The ability to translate data into meaningful efficacy, safety, and clinical endpoints is pushing the current probability of clinical success from 1 in 10 to 3 in 10 – a significant impact in today’s drug discovery and development paradigm,” he added.

InveniAI and Kyowa Kirin have been collaborating since 2018 and have expanded the framework of their collaboration twice so far (2020 and 2021)*. This milestone achievement is the result of the first joint research to maximize the portfolio value that began in 2018. In addition to the above-mentioned projects, there are ongoing projects aimed at discovering new drug candidates in several disease areas.

Read More About Aithority News : Fraud Mitigation Receives a Boost with SEON’s ML-based Blackbox Update

[To share your insights with us, please write to sghosh@martechseries.com]